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TRIM33 switches off Ifnb1 gene transcription during
the late phase of macrophage activation
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Despite its importance during viral or bacterial infections, transcriptional regulation of the
interferon-b gene (Ifnb1) in activated macrophages is only partially understood. Here we
report that TRIM33 deﬁciency results in high, sustained expression of Ifnb1 at late stages of
toll-like receptor-mediated activation in macrophages but not in ﬁbroblasts. In macrophages,
TRIM33 is recruited by PU.1 to a conserved region, the Ifnb1 Control Element (ICE), located
15 kb upstream of the Ifnb1 transcription start site. ICE constitutively interacts with Ifnb1
through a TRIM33-independent chromatin loop. At late phases of lipopolysaccharide
activation of macrophages, TRIM33 is bound to ICE, regulates Ifnb1 enhanceosome loading,
controls Ifnb1 chromatin structure and represses Ifnb1 gene transcription by preventing
recruitment of CBP/p300. These results characterize a previously unknown mechanism of
macrophage-speciﬁc regulation of Ifnb1 transcription whereby TRIM33 is critical for Ifnb1 gene
transcription shutdown.
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I
n response to viral or bacterial infections, germ line-encoded
pattern recognition receptors induce type I interferon (IFN-I,
encoded by 14 Ifna and 1 Ifnb genes in mice) gene
transcription in myeloid and non-myeloid cells1. The secreted
type I IFNs act early and transiently during the innate immune
response to prime adaptive immunity and then type I Ifn gene
transcription is shut down2. This transient expression of IFN-I is
physiologically important. Whereas early IFN-I expression is
important to control infection, pathogens that can overcome this
initial control beneﬁt from IFN-I mediated immune system
suppression3,4.
Among type I Ifn genes, Ifnb1 gene regulation has been a
model system to study inducible transcription. After pattern
recognition receptor-mediated activation, a group of transcription
factors, including IRF3/IRF7, NF-kB and ATF2/c-jun,
cooperatively binds to a regulatory sequence located between
 102 and  47 bp upstream of the Ifnb1 transcriptional start
site (TSS) to form the Ifnb1 enhanceosome. This enhanceosome
recruits CBP/p300 for acetylation of histone H3 and permits
recruitment of chromatin-remodeling complexes for initiation of
transcription5.
Monocyte/macrophage-speciﬁc regulation of Ifnb1 gene
transcription has only been observed in the modulation of the
transcriptional activity of IRF3. In monocytes, a PU.1-binding
site located in the enhanceosome is constitutively bound by a
IRF8/PU.1 myeloid complex that creates a preformed activation
complex. This myeloid complex can recruit IRF3 through direct
IRF3/IRF8 interaction and is involved in the rapid transcription
of Ifnb1 observed in monocytes after pathogenic stimulation6.
Conversely, transcriptional regulator MafB can impair the
interactions between IRF3 bound to the enhanceosome and co-
activators, and thus negatively regulates Ifnb1 transcription7.
Finally, binding of transcriptional regulator YY1 to different sites
within the enhanceosome has been shown to result in activation
(at the beginning) or repression (at the end) of Ifnb1 gene
transcription in ﬁbroblasts8–10. Altogether, these results point to
the enhanceosome as a regulator of both initiation and
termination of the Ifnb1 transcription cycle and of monocyte/
macrophage-speciﬁc regulation of Ifnb1 transcription.
The tripartite motif (TRIM) protein family is characterized by
a shared N-terminal structure consisting of a RING, two B-box
domains, a coiled-coil domain and, for most of the TRIM family
members, an E3 ubiquitin ligase activity11. TRIM33, together
with TRIM24, TRIM28 and TRIM66, form a sub-family of TRIM
proteins characterized by a C-terminal plant homeodomain
juxtaposed to a bromodomain12. These TRIM proteins do not
directly bind to DNA but can be recruited by DNA-binding
proteins, such as nuclear receptors13, SMAD14, PU.1 or TAL-1
(refs 15,16), to act as transcriptional regulators.
A large number of TRIM proteins are innate immune
enhancers and act at multiple levels in signalling pathways,
including production and action of IFN-b to confer antiviral
and antibacterial cytokine production17,18. As for the TRIM33
sub-family, TRIM24 represses the viral-defense IFN response
in hepatocytes as a consequence of repression of VL30
transcription13,19. Although these TRIM24 mediated repressions
are potentiated by TRIM33, TRIM33 deﬁciency alone cannot
elicit the IFN response in hepatocytes13,19. TRIM24 also acts as a
negative regulator of the IFN/signal transducers and activators of
the transcription signalling pathway13,19, and TRIM33 is essential
for cytosolic RNA-induced NLRP3 inﬂammasome activation20.
However, up to now, no TRIM protein has been shown to directly
regulate Ifnb1 gene transcription after recruitment to an Ifnb1
regulatory sequence.
We have previously shown that TRIM33 can interact with
PU.1 to repress its transcriptional activity during haematopoiesis
and suggested that TRIM33 may regulate myeloid fate and have a
role in macrophages15. Here, we show that TRIM33 deﬁciency in
macrophages results in sustained expression of Ifnb1 during
the late phases of macrophages activation. Our results indicate
that TRIM33, recruited by PU.1 on a distal regulatory element
of the Ifnb1 gene, regulates Ifnb1 enhanceosome loading and
shuts down Ifnb1 gene transcription during the late stages
of lipopolysaccharide (LPS) activation of macrophages by
preventing recruitment of CBP/p300.
Results
TRIM33 controls Ifnb1 expression in activated macrophages.
Trim33ﬂ/ﬂ mice were crossed with mice expressing the Cre
recombinase from the endogenous Lysozyme2 locus (LyzCre) to
generate Trim33 / mice. Trim33 / mice did not display
developmental abnormalities and were healthy. PCR genotyping
of puriﬁed haematopoietic cell populations showed deletion
of Trim33 in monocytes, bone-marrow-derived macrophages
(BMDM), peritoneal macrophages (PMs) and neutrophils but not
in myeloid progenitors, nor in B lymphocytes (Fig. 1a, upper
panels and Supplementary Fig. 1a). The deletion of the Trim33
gene allele was associated with a loss of TRIM33 expression in
BMDM (Fig. 1a, lower panel).
The effects of Trim33 deletion on Ifnb1 expression in
macrophages were studied by comparing kinetics of Ifnb1 mRNA
levels in wild-type (WT) or Trim33 / BMDM and PM, upon
TLR4 activation by LPS or upon TLR3 activation by poly(I:C).
These two activation protocols mimic bacterial (LPS) or viral
(poly(I:C)) infections. A rapid early increase of Ifnb1 mRNA
levels was observed in WT and Trim33 / BMDM or PM
activated by LPS (Fig. 1b). Thereafter, Ifnb1 mRNA levels
decreased from 2h in WT BMDM (or 4 h in WT PM) and
returned to basal levels by 6 h in WT BMDM and PM. In
contrast, although Ifnb1 mRNA levels decreased between 2 and
4 h, Ifnb1 mRNA levels began to rise signiﬁcantly by 6 h and
remained high 24 h after LPS activation in Trim33 / BMDM
or PM (Fig. 1b). This late sustained expression of Ifnb1 was also
observed when BMDM and PM were stimulated by poly(I:C)
with Ifnb1 mRNA levels being much higher at all late time points
in poly(I:C) treated Trim33 / BMDM compared with WT
(Supplementary Fig. 1b). The increased Ifnb1 mRNA levels in
Trim33 / BMDM activated with LPS correlated with increased
levels of secreted IFN-b (Fig. 1c). Finally, using a sub-optimal
concentration of LPS (0.1 ngml 1) which did not activate Ifnb1
in WT BMDM, we showed, in LPS-activated Trim33 /
BMDM, an increased expression of genes whose transcription is
dependent on IFN-b and occurs late during LPS activation
(Fig. 1d). This increased expression was not accounted for by
different responses of WT and Trim33 / BMDM to IFN-b
(Supplementary Fig. 1c) and could be obtained after addition of
IFN-b during the late phases of LPS activation of WT BMDM
(Supplementary Fig. 1d). Altogether, these results show that
TRIM33 deﬁciency is associated with increased Ifnb1mRNA level
associated with IFN-b secretion during the late stages of LPS
activation of BMDM.
To study if TRIM33 deﬁciency affects the expression of other
Ifn genes, quantitative RT-PCR was performed and showed
similar kinetics of Ifna mRNA levels in WT or Trim33 /
BMDM with no late increased expression of Ifna mRNA levels in
Trim33 / BMDM (Fig. 1e). Finally, highly efﬁcient shRNA-
mediated depletion of TRIM33 in NIH3T3 cells (NIH3T3
TRIM33 ; Supplementary Fig. 1e) did not modify kinetics of
Ifnb1 mRNA levels in response to poly(I:C) (Fig. 1f), indicating
cell-speciﬁcity in the regulation of Ifnb1 expression by TRIM33.
Potential direct or indirect roles for TRIM33 in Ifnb1
expression were addressed in ‘rescue’ experiments in which
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Figure 1 | TRIM33 regulates Ifnb1 gene expression in activated macrophages. (a) Genomic PCR detection of Trim33 in BMDM and PM (top) and western
blot analysis of TRIM33 in BMDM fromWTand Trim33 / mice (bottom). (b) Kinetics of Ifnb1 mRNA levels in WTand Trim33 / BMDM (left panel) or
PM (right panel) after activation with LPS. Mean±s.e.m., n¼ 3 to 6. (c) IFN-b protein levels in supernatants of non-activated and LPS-activated WT and
Trim33 / BMDM. Mean±s.e.m., n¼4. (d) Relative mRNA levels of Ifnb1 and IFN-b target genes in Trim33 / BMDM versus WT BMDM treated with
LPS (0.1 ngml 1) for 3 or 24 h. Mean±s.e.m., n¼ 3. (e) Kinetics of Ifna mRNA levels in WT and Trim33 / BMDM activated with LPS. Mean±s.e.m.,
n¼ 3. (f) Kinetics of Ifnb1 mRNA levels in NIH3T3 cells expressing a shRNA targeting Trim33 (NIH3T3 TRIM33 ) or luciferase (NIH3T3 TRIM33þ ) and
activated with poly(I:C). Mean±s.e.m., n¼ 3. (g) Kinetics of Ifnb1 mRNA levels in WT and Trim33 / iM treated for the indicated times with LPS.
Mean±s.e.m., n¼ 3. (h) Relative expression of Ifnb1 mRNA 0, 2 and 8 h after LPS treatment of Trim33 / iM transduced with a lentivirus coding for GFP
(iM Trim33 / þGFP), for full-length ﬂag-TRIM33 and GFP (iM Trim33 / þ ﬂag-TRIM33) or for ﬂag-TRIM33 mutants lacking the coiled-coil domain
(iM Trim33 / þ ﬂag-DCC), the ubiquitin ligase activity (iM Trim33 / þ ﬂag-DUb) or the SMAD-interaction domain (iM Trim33 / þ ﬂag-DSMAD).
Mean±s.e.m., n¼ 5. All qRT-PCR data are normalized to HPRT and, unless otherwise indicated, presented relative to expression of untreated WT cells.
*Po0.05; **Po0.01 and ***Po0.001, Mann–Whitney test.
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TRIM33 protein was added back to LPS-activated immortalized
Trim33 / macrophages (iM)21. As anticipated, Trim33 /
iM bore the expected deletion of Trim33 gene and these cells
expressed no TRIM33 protein (Supplementary Fig. 1f). Ifnb1
mRNA levels increased 1 h after LPS activation of WT and
Trim33 / iM and peaked at 2 h with twofold higher observed
expression in WT iM than in Trim33 / iM (Fig. 1g). As
anticipated, Ifnb1 mRNA levels in WT iM then dropped, whereas
in Trim33 / iM, Ifnb1 mRNA levels remained high (Fig. 1g).
Thus, LPS activation of Trim33 / iM mimicked the late phase
of the Ifnb1 mRNA kinetics seen in Trim33 / BMDM. To
address whether expression of ectopic TRIM33
could rescue Ifnb1 downregulation at late time points,
a ﬂag-TRIM33-IRES-GFP (or GFP alone) construct was
expressed in Trim33 / iM and cells were stimulated with
LPS (Fig. 1h). The full-length exogenous TRIM33 protein
restored Ifnb1 downregulation at late time points of LPS
activation of Trim33 / iM (Fig. 1h) indicating a role for
TRIM33 in the regulation of Ifnb1 gene expression during LPS
activation of macrophage.
To determine the TRIM33 protein domains involved in Ifnb1
regulation, mutant ﬂag-TRIM33-IRES-GFP constructs lacking
the coiled-coil domain (ﬂag-DCC), the ubiquitin ligase activity
(ﬂag-DUb) or the Smad-interaction domain (ﬂag-DSmad) were
expressed in Trim33 / iM (Supplementary Fig. 1g). The
ﬂag-DUb and the ﬂag-DSmad rescued normal Ifnb1 expression at
late time points of LPS-activated Trim33 / iM whereas the
ﬂag-DCC did not rescue normal proﬁle of Ifnb1 expression in
activated Trim33 / iM (Fig. 1h). These results indicate that the
Smad-interaction and ubiquitin ligase domains are not necessary
for TRIM33 regulation of Ifnb1 expression and suggest that
TRIM33 is part of a regulatory complex that regulates Ifnb1
transcription.
Altogether, these results reveal a role for TRIM33 in the
regulation of Ifnb1 expression speciﬁcally in downregulating its
expression during the late stages of macrophage activation.
TRIM33 binds a distal Ifnb1 regulatory element. TRIM33
ChIP-seq data obtained from the RAW 264.7 murine macrophage
cell line or from BMDM treated with LPS for 24 h showed a single
TRIM33 peak at the Ifnb1 locus that overlapped with a PU.1 peak
located 15 kb upstream from the Ifnb1 TSS (Fig. 2a). Interestingly,
no TRIM33 occupancy was observed at the PU.1 peak located just
upstream the Ifnb1 promoter corresponding to the enhanceo-
some-binding sites. We called this  15 kb region the Ifnb1
Control Element (ICE). Recently, the human homologue of ICE,
named L2, has been shown to be a virus-inducible enhancer of
Ifnb1 in non-myeloid cells where it displays promoter and
enhancer activities22.
Constitutive TRIM33 occupancy at ICE was observed in
BMDM although occupancy appeared to increase at late time
points (24 h) following LPS activation (Fig. 2b, left panel). PU.1
binding at the Ifnb1 promoter and at ICE was constitutive and
detected in WT and Trim33 / BMDM (Fig. 2b, middle and
right panels) indicating that PU.1 binding to ICE was not
TRIM33-dependent. Finally, no TRIM33 binding was observed
on the Ifnb1 promoter or ICE in NIH3T3 cells (Fig. 2c),
indicating macrophage speciﬁcity of TRIM33 in binding to ICE.
To determine if TRIM33-mediated regulation of Ifnb1 in
myeloid cells can be obtained in NIH3T3 by simultaneous
expression of PU.1 and TRIM33, NIH3T3 cells were transduced
with a PU.1 expressing lentivirus (Supplementary Fig. 2a). PU.1
expressing NIH3T3 were then transduced with the lentivirus
that promoted efﬁcient shRNA-mediated depletion of TRIM33
(Supplementary Fig. 1e) and NIH3T3 PU.1þTRIM33þ and
NIH3T3 PU.1þTRIM33 responses to poly(I:C) were studied.
Whereas TRIM33 deﬁciency did not modify kinetics of Ifnb1
mRNA levels in response to poly(I:C) in normal NIH3T3 cells
(Fig. 1f), TRIM33 deﬁciency increased Ifnb1 mRNA levels in
NIH3T3 PU.1þ cells treated with poly(I:C) but did not result in
sustained expression of Ifnb1 during the late stages of poly(I:C)
activation (Fig. 2d). These results show that TRIM33 can repress
Ifnb1 expression in presence of PU.1 and indicate that additional
factors that are not present in NIH3T3 cells are required for
TRIM33-mediated late downregulation of Ifnb1 expression.
To study the effect of ICE on Ifnb1 promoter activity in
myeloid cells, we used RAW 264.7 cells in which LPS regulates
Ifnb1 gene expression (Supplementary Fig. 2b). RAW 264.7 cells
were transfected with luciferase reporter constructs containing a
391 bp fragment of the Ifnb1 promoter preceded by a 408 bp
fragment corresponding to the central region of ICE (ICE-Ifnb1
Prom-Luc) or the fragment containing the Ifnb1 promoter alone
as a control sequence (Ifnb1 Prom-Luc). Transcriptional activity
of ICE-reporter (ICE-Ifnb1 Prom-Luc) showed four to tenfold
less activity than the promoter reporter in LPS-activated RAW
264.7 cells indicating that ICE functions as a cis-acting
transcriptional repressor element in RAW 264.7 cells (Fig. 2e).
To study the role of ICE in RAW 264.7 and NIH3T3 cells, we
used a CRISPR/Cas9 lentiviral system to deliver Cas9 and gRNA
(Supplementary Fig. 2c). Using this system, we had to screen 200
RAW 264.7 clones to get one RAW 264.7 clone with monoallelic
deletion of ICE (Supplementary Fig. 2d). This low efﬁciency of
recombination in RAW 264.7 cells does not favour the use of
transient transfection for CRISPR/Cas9-mediated deletion of ICE,
transient transfection efﬁciency in RAW 264.7 being 15%
compared with 90% using the lentiviral system. RAW 264.7
and NIH3T3 clones bearing this deletion on one allele
(termed RAW ICEþ / and NIH3T3 ICEþ / , respectively;
Supplementary Fig. 2d) were analysed for Ifnb1 expression after
LPS or poly(I:C) activation. In LPS-activated RAW WT cells,
Ifnb1 mRNA levels increased during the ﬁrst 4 h and then
gradually decreased (Supplementary Fig. 2e). In contrast, whereas
Ifnb1 mRNA levels increased comparably in RAW ICEþ / cells,
they subsequently remained stable (Fig. 2f and Supplementary
Fig. 2e). In NIH3T3 WT and ICEþ / cells activated with
poly(I:C), kinetics of Ifnb1 mRNA levels were similar (Fig. 2g and
Supplementary Fig. 2f). These results indicate that ICE plays a
role in the negative regulation of Ifnb1 expression at late stages of
LPS activation in RAW cells.
Sequential deletions centered on the PU.1/TRIM33-binding
site of ICE were performed in RAW 264.7 cells using CRISPR/
Cas9 technology (Supplementary Fig. 2g). Of the 96 clones
screened, two carried a biallelic deletion of ICE (Supplementary
Fig. 2d). Two RAW 264.7 clones bearing a 100 or 176 bp deletion
on the two Ifnb1 alleles (termed #34 and #15; Supplementary
Fig. 2g) were analysed for Ifnb1 expression after LPS or poly(I:C)
activation. In the two clones high and sustained Ifnb1 mRNA
levels were found but only after LPS or poly(I:C) activation, with
the highest increase being obtained during the late phase of
activation (Fig. 2h).
Altogether, these results show that ICE functions as a cis-acting
transcriptional repressor element of the Ifnb1 gene activation in
macrophages and indicate that TRIM33 and PU.1 bound to ICE
may have an important role in Ifnb1 gene transcription shutdown
during the late phase of macrophage activation.
ICE chromatin structure and interaction with Ifnb1 in BMDM.
Comparison of reported human and mouse ICE sequences
showed 70% sequence homology around the TRIM33/PU.1 peak
with consensus binding motifs for AP-1, NF-kB and IRF
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transcription factors (Supplementary Fig. 3a, left panel). Fur-
thermore, c-JUN, the p65 subunit of NF-kB and IRF3, three
transcription factors that form the Ifnb1 enhanceosome and
regulate its transcriptional activity, were also bound to ICE three
hours after LPS activation of BMDM (Supplementary Fig. 3a,
right panel; data from ref. 23). We studied a possible TRIM33
dependency of c-jun and p65 binding to ICE but found that
TRIM33 deﬁciency did not modify the kinetics of their binding to
ICE (Fig. 3a).
Analysis of ICE chromatin structure in macrophages showed that
this region is characterized by high levels of H3K4me3 and
H3K27ac modiﬁcation, ﬂanked by regions enriched for H3K4me1,
all features of transcriptionally active promoters (Supplementary
Fig. 3b, red graph, data from ref. 24). These epigenetic
modiﬁcations are present in short-term haematopoietic stem cells
(ST-HSCs) and in myeloid cells, but not in mature erythroid and
lymphoid cells (Supplementary Fig. 3b). We studied the effect of
TRIM33 deﬁciency on the chromatin structure of ICE in non-
activated and LPS-activated BMDM to ask whether TRIM33 has a
role in histone modiﬁcation of this region. Before and during LPS
activation of WT and Trim33 / BMDM, no signiﬁcant
differences in H3K4me1 levels on ICE could be detected
(Supplementary Fig. 3c). ChIP and ChIP-seq analyses showed a
constitutive binding of RNA Polymerase II (Pol II) and
constitutively high levels of H3K4me3 on ICE (Fig. 3b). Prior to
LPS activation, histone H3 acetylation (H3ac) on ICE was similar in
WT and Trim33 / BMDM (Fig. 3c, left panel). During LPS
activation, H3ac on ICE did not change in WT BMDM but was
transiently increased 10 h after LPS activation in Trim33 /
BMDM (Fig. 3c, left panel). This increased H3ac on ICE in
Trim33 / BMDM was associated with transient increase of CBP/
p300 histone H3 acetyl-transferase (HAT) -binding on ICE 10h
after LPS activation (Fig. 3c, right panel). Collectively, database
analyses and our results suggest that, in BMDM, ICE exhibits a
promoter-like chromatin signature established early during myeloid
differentiation. TRIM33 deﬁciency did not modify ICE chromatin
signature and only led to transient increases of H3ac and CBP/p300
recruitment on ICE whereas a sustained high expression of Ifnb1
was observed in LPS-activated Trim33 / BMDM suggesting that
TRIM33 bound to ICE might act at a distance.
To investigate how TRIM33 bound to ICE, that is located 15 kb
upstream of the Ifnb1 transcription unit, may regulate Ifnb1
transcription, chromosome conformation capture experiments
followed by deep sequencing (3C-seq) were performed in WT
and Trim33 / BMDM before and after LPS activation. ICE
(Fig. 3d, top) and the Ifnb1 gene (Fig. 3d, bottom), including its
promoter, were used as viewpoints. In WT BMDM, both
viewpoints showed a loop between ICE and the Ifnb1 gene
before LPS activation and a twofold stronger interaction 24 h after
LPS activation (Fig. 3d, blue curves). Interestingly, Trim33
deletion did not signiﬁcantly modify DNA looping in this region,
even after LPS treatment (Fig. 3d, compare red (Trim33 / ) and
blue (WT) curves). These results indicate that ICE interacts with
the Ifnb1 proximal region in a constitutive and TRIM33-
independent manner, but that this interaction is strengthened
following LPS stimulation.
TRIM33 represses Ifnb1 by preventing CBP/p300 recruitment.
To characterize how TRIM33 might regulate Ifnb1 transcription,
we studied the effect of TRIM33 deﬁciency on temporal binding
of p65 and c-jun to the enhanceosome as these two factors are
major regulators of its activity. As anticipated, in WT BMDM,
c-jun and p65 were recruited to the Ifnb1 promoter at early times
following LPS activation (1 h), but their binding returned to basal
levels after 24 h (Fig. 4a). In contrast, in the absence of TRIM33,
p65 and c-jun binding to the Ifnb1 promoter was maintained
even 24 h after activation (Fig. 4a). Thus, TRIM33 deﬁciency
maintains enhanceosome loading by c-jun and p65 during the
late phases of LPS activation.
We then determined the effect of TRIM33 deﬁciency on Ifnb1
transcription and chromatin structure during LPS activation of
BMDM. On the Ifnb1 TSS, low levels of paused Pol II were
observed before LPS stimulation in both WT and Trim33 /
cells (Fig. 4b, upper left panel). In WT BMDM, Pol II occupancy
at TSS and in Ifnb1 30 region increased after 1 h of stimulation
and then was lost at 4 h (Fig. 4b, upper panels). In Trim33 /
BMDM, Pol II occupancy similarly increased after 1 h of
stimulation but its levels were maintained up to 24 h (Fig. 4b,
upper panels). H3K4me3 levels were transiently increased in WT
BMDM after 4 h of LPS stimulation, whereas in Trim33 /
BMDM, persistent and high levels of H3K4me3 were also
observed up to 24 h (Fig. 4b, lower panel and right panel). These
observations suggest that the paused Pol II seen in the absence of
LPS treatment is used for rapid Ifnb1 transcription immediately
following LPS stimulation in WT and Trim33 / BMDM.
Then, in WT BMDM, Pol II drops off and Ifnb1 transcription
ceases, whereas in Trim33 / BMDM, continued Pol II
occupancy and H3K4me3 promote sustained Ifnb1 transcription.
Prior to LPS activation, histone H3ac on the Ifnb1 promoter
was similar in WT and Trim33 / BMDM (Fig. 4c). This H3ac
increased at 1 h after LPS activation of WT and Trim33 /
BMDM. It then returned to basal levels in WT BMDM, whereas a
5- to 8-fold increase in H3ac was observed after 10 and 24 h in
Trim33 / BMDM (Fig. 4c). H3ac on the Ifnb1 promoter
in LPS-activated Trim33 / iM mimicked that observed in
Trim33 / BMDM (Fig. 4d). Expression of ectopic full-length
ﬂag-TRIM33 in Trim33 / iM led to decreased H3ac on the
Ifnb1 promoter 7 h after LPS stimulation (Fig. 4d), whereas the
ﬂag-DCC that could not rescue normal Ifnb1 expression in
Trim33 / iM (Fig. 1h) did not decrease H3ac on the Ifnb1
promoter 7 h after LPS stimulation (Fig. 4d). These results
indicate a link between TRIM33 and the regulation of H3ac on
the Ifnb1 promoter.
Increased H3ac on the Ifnb1 promoter in LPS-activated
Trim33 / BMDM indicated a possible role for TRIM33 in
regulating the equilibrium between recruitment and/or activity
of HAT and histone deacetylases (HDAC). Treatment of
LPS-activated WT BMDM with trichostatine A, an inhibitor of
HDACs, did not result in sustained Ifnb1 expression, whereas it
did alter expression of genes regulated by HDACs (Fig. 4e, left
panel and Supplementary Fig. 4a). Conversely, the increased
H3ac was found to be associated with CBP/p300 HAT binding
on the Ifnb1 promoter 10 and 24 h after LPS activation in
Trim33 / BMDM (Fig. 4e, right panel). As total CBP protein
levels were similar in WT and Trim33 / BMDM (Fig. 4f),
these results indicated that TRIM33 deﬁciency promotes CBP
recruitment. To determine the importance of CBP/p300 activity
in the phenotype of Trim33 / BMDM, we used C646,
a small-molecule inhibitor that efﬁciently competes with
CBP/p300 substrates25. Adding C646 2 h after LPS induction
did not modify Ifnb1 expression in WT BMDM, but reversed the
high sustained Ifnb1 transcription level in Trim33 / BMDMs
at both 10 and 24 h (Fig. 4g). This reversion was associated with
decreased levels of H3ac (Fig. 4h) and reduced Pol II occupancy
within the Ifnb1 promoter region in Trim33 / BMDM
(Supplementary Fig. 4b).
Altogether, these results show that enhanced CBP/p300
recruitment and activity at late times of activation is required
for sustained Ifnb1 expression in Trim33 / BMDM and that
TRIM33 may regulate Ifnb1 expression at late times by
preventing the recruitment of CBP/p300.
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binding at ICE in WT and Trim33 / BMDM treated for the indicated times with LPS. Mean±s.e.m., n¼ 2 to 4. (b) ChIP-qPCR analysis of RNA Pol II
(upper left panel) and H3K4me3 (lower left panel) at ICE in WTand Trim33 / BMDM treated for the indicated times with LPS. Mean±s.e.m., n¼ 3 to 5.
(Right panel) UCSC genome browser images showing H3K4me3 ChIP-seq proﬁles at ICE in WT and Trim33 / BMDM treated for the indicated
times with LPS. (c) ChIP-qPCR analysis of acetylated histone H3 (left panel) and CBP/p300 (right panel) at ICE in WTand Trim33 / BMDM treated for
the indicated times with LPS. Mean±s.e.m., n¼4. **Po0.01, Mann–Whitney test. (d) DNA looping at the Ifnb1 locus was determined by 3C-seq performed
before or 24 h after LPS activation of WTand Trim33 / BMDM using either ICE (upper panel) or Ifnb1 gene (lower panel) as viewpoints (shown by an eye
and a yellow band). Data represent normalized reads per million (r.p.m.) per restriction fragment. The x axis shows the genomic coordinates of the Ifnb1
locus. The positions of the EcoRI restriction sites and the TRIM33 ChIP-seq proﬁle in BMDM are indicated on the top.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9900 ARTICLE
NATURE COMMUNICATIONS | 6:8900 |DOI: 10.1038/ncomms9900 |www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Discussion
Although IFN-a and IFN-b share the same receptor, IFN-b seems
to be the major immune-suppressive IFN26 and macrophage-
restricted synthesis of IFN-b can contribute to protective or
pathological immune responses in the lung27. Surprisingly,
despite the importance of IFN-b production by macrophages,
no cis- or trans-acting factor that might confer a myeloid
speciﬁcity to Ifnb1 gene transcription has been characterized. The
data presented in this study provide evidence of a previously
unappreciated regulation of Ifnb1 transcription in macrophages
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through a macrophage-restricted TRIM33 recruitment on a
regulatory sequence, designated as ICE, located 15 kb upstream
from the Ifnb1 TSS.
ICE has an open-chromatin structure highly conserved during
myeloid differentiation and characterized by Pol II occupancy
and tri-methylation of H3K4, two features that are not typical
marks of an enhancer or a repressor. In addition to a PU.1-
binding site, ICE contains DNA-binding sites for transcriptional
regulators such as IRF3, c-jun or p65 that are also part of the
enhanceosome. ICE has been recently shown to interact with the
Ifnb1 promoter in human ﬁbroblasts in the absence of any viral
infection22. Here, we show that ICE can also interact with the
Ifnb1 promoter in non-activated macrophages. These combined
ﬁndings indicate that ICE/Ifnb1 loop is cell-type independent,
stable and independent of viral or bacterial stimulation. Such
enhancer or repressor loop stability has been described during
development where they are associated with paused polymerase28
and in human ﬁbroblasts where TNF-a-responsive enhancers
contact their target promoters before TNF-a activation29.
Transient transfection in ﬁbroblast cell lines shows that ICE
acts as an enhancer of Ifnb1 promoter activity, but only after viral
infection22. In contrast, in macrophages, ICE acts as a repressor
of Ifnb1 promoter activity during LPS activation. Furthermore,
the high and sustained expression of Ifnb1 in LPS- or poly(I:C)-
activated RAW cells where both alleles of ICE are deleted using
lentiviral delivery of Cas9 and gRNA indicates that ICE has a
repressor activity when these cells are stimulated. Although the
lentiviral system used might increase the frequency of off-target
effects30,31, the similar results obtained with three different clones
and with different gRNAs make off-target effects less likely. Use
of recombinant Cas9 protein32 or highly efﬁcient transient
transfection of RAW cells will reduce off-target effects and
deﬁnitively show that ICE is a unique element that acts as an
enhancer in ﬁbroblasts, but displays promoter marks and acts as a
repressor at late stages of LPS activation of macrophages. These
opposite roles of ICE in ﬁbroblasts and macrophages might be
linked to recruitment of distinct proteins in the two cell types.
Indeed, PU.1, which is not expressed in ﬁbroblasts, is bound to
ICE in macrophages and might be involved in the cell-speciﬁc
function of ICE. Ectopic PU.1 expression in TRIM33þ and
TRIM33 NIH3T3 cells indicates that TRIM33-mediated
repression of Ifnb1 is dependent on PU.1 expression. However,
in ﬁbroblasts activated with poly(I:C), PU.1 expression associated
with TRIM33 deﬁciency does not result in the sustained Ifnb1
expression observed in poly(I:C)-activated Trim33 / BMDM.
This result suggests that factors present in BMDM, but not in
ﬁbroblasts, are required for Ifnb1 repression during the late stages
of BMDM activation. Amongst haematopoietic-restricted PU.1
partners, IRF8 and IRF3 that regulate Ifnb1 activation in
BMDM6,33 are good candidates to cooperate with TRIM33 for
Ifnb1 repression during the late stages of BMDM activation.
Several TRIM proteins regulate production and action of
IFN-b during innate immune response. TRIM6 is a positive
regulator of IFN-b and is critical for IFN-b-mediated antiviral
response34, TRIM25 is essential for RIG-I-mediated-type I
IFN induction35, TRIM21 regulates IRF3-dependent IFN-b
expression36 and TRIM56 modulates STING and subsequent
IFN-b induction37. Here, we show the implication of TRIM33 in
the transcriptional regulation of Ifnb1. Interestingly, TRIM33
deﬁciency did not alter the initial activation of Ifnb1 transcription
after LPS activation of macrophages but impaired repression
of Ifnb1 expression during the late stages of this activation.
Together with the continuous binding of TRIM33 on ICE, the
complementation of the Ifnb1 phenotype in macrophages by re-
expression of TRIM33 in Trim33 / immortalized macrophages
suggested a direct role of TRIM33 in Ifnb1 transcription and
indicated that the activity and/or substrate availability of TRIM33
regulated Ifnb1 expression at the end of LPS activation of
macrophages.
Two lines of evidence suggest that, during the late stages of LPS
activation of BMDM, TRIM33 represses Ifnb1 expression through
modulation of CBP/p300 recruitment and/or activity at the
Ifnb1 promoter. First, TRIM33 inactivation led to recruitment of
CBP/p300 at the Ifnb1 promoter and enhanced H3ac. Second,
CBP/p300 activity is critical for enhanced Ifnb1 transcription
at late stages as chemical inhibition of CBP/p300 enzymatic
activity could restore the regulated expression of Ifnb1 gene in
Trim33 / macrophages. As CBP/p300 acts as a switch to
initially turn on Ifnb1 gene transcription38, these results indicated
that TRIM33 might turn off Ifnb1 transcription during the
late stages of LPS activation of macrophages by impairing the
CBP/p300 recruitment and activity at the Ifnb1 promoter. This
TRIM33-dependent recruitment and activity of CBP/p300 could
be direct and/or mediated by trans-acting factors such as p65 that
are, in Trim33 / BMDM, loaded onto the enhanceosome
during the late phases of LPS activation. However, as PU.1 can
interact with CBP/p300 (refs 39,40) and TRIM33, we propose a
model where CBP/p300 and TRIM33 compete for PU.1 binding
during LPS activation of BMDM. During the initial stages of LPS
activation, CBP/p300 recruited by the enhanceosome might
activate Ifnb1 transcription, whereas during the late stages of LPS
activation, TRIM33 might interact with PU.1, impair PU.1/CBP/
p300 interaction and shut down Ifnb1 transcription (Fig. 4i).
Numerous studies have shown the complexity of Ifnb1 gene
transcriptional regulation. Our data describe a new regulatory
layer through identiﬁcation of cis- and trans-acting elements that
regulate Ifnb1 gene transcription at speciﬁc steps of macrophage
activation, but not in ﬁbroblasts. These ﬁndings not only provide
Figure 4 | TRIM33 regulates Ifnb1 gene expression through inhibition of CBP/p300 recruitment. (a) ChIP-qPCR of p65 (left panel) and c-jun (right
panel) at the Ifnb1 promoter in WT and Trim33 / BMDM treated with LPS. Mean±s.e.m., n¼ 2 to 4. (b, top) ChIP-qPCR of RNA Pol II at the Ifnb1
promoter (left panel) and at a region located þ 2.5 kb from TSS (middle panel) in WTand Trim33 / BMDM treated with LPS. Mean±s.e.m., n¼ 3 to 5.
(Bottom) ChIP-qPCR (left panel) and ChIP-seq (right panel) of H3K4me3 at the Ifnb1 promoter in WT and Trim33 / BMDM treated with LPS.
Mean±s.e.m., n¼ 3. (c) ChIP-qPCR of H3ac at the Ifnb1 promoter in WTand Trim33 / BMDM treated with LPS. Mean±s.e.m., n¼4. (d) ChIP-qPCR of
H3ac at the Ifnb1 promoter in Trim33 / iM expressing GFP (iM Trim33 / þGFP), full-length ﬂag-TRIM33 and GFP (iM Trim33 / þ ﬂag-TRIM33), or
ﬂag-TRIM33 lacking the coiled-coil domain and GFP (iM Trim33 / þ ﬂag-DCC), and treated for 0 or 7 h with LPS. Mean±s.e.m., n¼ 3. (e, left) Relative
expression of Ifnb1 mRNA in LPS-activated WT BMDM in presence or absence of Tricostatin A (TSA), added 4 h after LPS stimulation. Mean±s.e.m., n¼ 3.
(Right) ChIP-qPCR of CBP/p300 binding at the Ifnb1 promoter in WT and Trim33 / BMDM treated with LPS. Mean±s.e.m., n¼4. (f) Western blot of
CBP in WT and Trim33 / BMDM treated with LPS. b-actin is shown as control. n¼4 independent experiments. (g) Kinetics of Ifnb1 mRNA levels in
LPS-activated WTand Trim33 / BMDM, in the presence (dotted lines) or absence (continuous lines) of C646. C646 was added 2 h after LPS stimulation
and Ifnb1 mRNA levels were determined. Mean±s.e.m., n¼ 8. (h) ChIP-qPCR of H3ac at the Ifnb1 promoter in LPS-activated WTand Trim33 / BMDM,
in the presence (hatched columns) or absence (solid columns) of C646. Data are presented relative to H3ac binding in untreated WT BMDM.
Mean±s.e.m., n¼ 2. (i) Schematic representation depicting the role of TRIM33 in the macrophage-restricted Ifnb1 gene transcription shut down.
*Po0.05 and **Po0.01, Mann–Whitney test.
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important insights into the cell-speciﬁc regulation of Ifnb1 gene
transcription but also extend the role of TRIM proteins as critical
regulators of the innate immune response.
Methods
Mice. To generate deletion of Trim33 in mature myeloid cells, Trim33ﬂ/ﬂ
C57Bl/6-CD45.2 mice15 were crossed with Lysozyme-Cre C57Bl/6-CD45.2 mice
(strain name: B6.129P2-Lyz2tm1(cre)Ifo/J, The Jackson Laboratory). Male and
female mice of 8–12 months of age were used. Experiments were performed in
compliance with European legislation and with the Ethics Committee of the French
Ministry of Agriculture (Agreement B9203202).
Cell culture. For BMDM generation, mouse bone marrow (BM) was ﬂushed out of
the tibiae, femora and humeri using a syringe with PBS, ﬁltered through a 70-mm
mesh ﬁlter (Becton Dickinson) to remove debris and pelleted by centrifugation.
Adherent cells were removed by incubating BM cells on culture dishes for 3 h in
IMDM supplemented with 10% foetal calf serum (FCS), 1% penicillin/strepto-
mycin (PS; Life Technologies) and 10 mM thioglycerol (Sigma Aldrich), then
non-adherent cells were cultured for 7 days on culture dishes in the same medium
supplemented with 25 ngml 1 mouse CSF1 (Miltenyi Biotec). On day 7, BMDM
were activated with LPS or poly(I:C) in IMDM supplemented with 2.5% FCS and
1% PS. For PMs, cells were collected with cold PBS and cultured for 2 h in RPMI
1640 medium (Life Technologies), supplemented with 10% FCS. All adherent cells
expressed F4/80 and were considered as PMs. PM were activated with LPS or
poly(I:C) in RPMI 1640 medium supplemented with 2.5% FCS and 1% PS. WT and
Trim33 / iM were generated as previously described21. Brieﬂy, BM cells isolated
from WT and Trim33 / mice were cultured in IMDM supplemented with 10%
FCS and 50 ngml 1 mouse CSF1 (Peprotech). After overnight culture, the cells
were transduced with a lentiviral vector expressing the SV40 large
T antigen (SFFV.Tag LV). Cells were then cultured in a chemically deﬁned medium
(SFM-macrophage medium, Life Technologies) supplemented with CSF1
(50 ngml 1). Single clones were isolated that expressed F4/80, CD11b but not Gr1.
The resulting clones, termed iM, were maintained in IMDM supplemented with
20% foetal bovine serum, 1% PS and 50 ngml 1 CSF1. iM were activated with LPS
in IMDM supplemented with 2.5% FCS and 1% PS. For cell lines, RAW 264.7 and
NIH3T3 cells were grown in DMEM (Life Technologies) supplemented with 10%
FCS and 1% PS. RAW 264.7 cells were activated with LPS in DMEM supplemented
with 1% FCS. Unless otherwise indicated, LPS (Sigma Aldrich) was used at
100 ngml 1, poly(I:C) at 30mgml 1, TSA (Sigma Aldrich) at 10 nM, and C646
(Merck Millipore) at 10mM. NIH3T3 were transfected with 10 mgml 1 poly(I:C)
(Sigma Aldrich).
Chromatin Immunoprecipitation (ChIP). Cells were ﬁxed with 1% formaldehyde
for 10min at 37 C, lysed in SDS lysis buffer (50mM Tris pH8, 10mM EDTA,
1% SDS, protease inhibitor cocktail (Roche)) and sonicated. Supernatant was
diluted 10 times in IP dilution buffer (16.7mM Tris pH8, 167mM NaCl, 1.2mM
EDTA, 1.1% TritonX-100, 0.01% SDS, protease inhibitor cocktail (Roche)) and
immunoprecipitations were carried out overnight with speciﬁc antibodies.
Immunoprecipitated chromatin was collected using Protein A Agarose/Salmon
Sperm DNA beads (Millipore) and, after washing and elution, reverse cross-linking
was carried out with 0.2M NaCl at 65 C overnight. The chromatin was then
digested by 20 mg of Proteinase K (Invitrogen) for 1 h at 45 C and isolated
by phenol–chloroform extraction. PCR reactions were performed using SYBR
Green PCR Master Mix (Applied Biosystems) and speciﬁc primers sequences
are listed below.
For sequencing, 10 ng of puriﬁed DNA from ChIP was adapter-ligated, PCR
ampliﬁed and sequenced on the Illumina Genome Analyzer IIx as single-end 50
base reads following Illumina’s instructions. Sequence reads were mapped to
reference genome mm9/NCBI37 using Bowtie v0.12.7.
3C-seq. 3C-seq was performed as previously described41, using EcoRI as ﬁrst
cutter and DpnII as second cutter. Brieﬂy, cells were ﬁxed with 2% formaldehyde
for 10min at room temperature, and nuclei were prepared by lysing cells in 10mM
Tris pH8, 10mM NaCl, 0.2% NP-40. Nuclei were lyzed in 0.5ml 1 EcoRI buffer
supplemented with 0.3% SDS for 1 h at 37 C. Triton X-100 was added at 2% ﬁnal
for another 1 h at 37 C. DNA was then digested with 400 units of EcoRI overnight
at 37 C. Samples were incubated for 25min at 65 C with 1.6% SDS, diluted to 7ml
with ligase buffer, supplemented with 1% Triton X-100 and incubated at 37 C for
1 h. Ligation was performed for 4 h at 16 C with 100 u T4 DNA ligase, then 300mg
proteinase K were added and samples were decrosslinked overnight at 65 C.
RNase (300 mg) was added for 45min at 37 C, and samples were extracted with
phenol/chloroform/isoamyl alcohol (25:24:1; PCI). After precipitation, samples
were digested with DpnII, extracted with PCI and precipitated, and ligated in 15ml
ligation buffer at 16 C for 4 h before another PCI extraction and precipitation.
Samples were ampliﬁed by PCR with the primers listed below, and PCR products
were puriﬁed on QIAprep columns (Qiagen). The resulting libraries were
sequenced on a Illumina HiSeq 2000 as single-end 100 bp reads. After trimming,
reads were aligned on the mm9 version of the mouse genome using Bowtie.
Results are presented as the number of reads per million reads per EcoRI fragment,
in the middle of each fragment.
Assay for IFN-b. WT and Trim33 / BMDM supernatants were collected
after LPS stimulation. ELISA was performed with LegendMax Mouse IFN-b kit
(Biolegend), according to manufacturer’s instructions.
Quantitative RT-PCR. Total RNA was extracted with the RNeasy Plus Micro kit
(Qiagen) and reverse transcribed with random primers and Superscript III (Life
Technologies). Quantitative PCR was performed using the Power SYBR green PCR
master mix (Applied Biosystems) in the 7900HT Fast Real-Time or the StepOne
PCR Systems (Applied Biosystems). Primer sequences are listed below.
Lentiviral vectors for rescue and knockdown. For rescue experiments in
Trim33 / iM, the lentiviral vector was constructed by inserting full-length
ﬂag-TRIM33 from the pSG5-ﬂag-TRIM33 (ref. 15) into the pTRIP/DU3-MND-
IRES-GFP vector, downstream the MND promoter, using the Gateway technology
(Life Technologies). Deletions of the coiled-coil domain (aa 321–457), the ubiquitin
ligase activity (aa 141–145) and the SMAD-interaction (aa 555–876) domain were
generated by PCR. The pTRIP/DU3-MND-GFP was used in control experiments.
NIH3T3 PU1þ cells were obtained by transducing a lentiviral vector pTRIP/DU3-
MND-PU.1-IRES-GFP. For TRIM33 knocking-down in NIH3T3 or NIH3T3
PU.1þ , the sequence of the shRNA targeting mouse Trim33 was obtained
from Sigma Aldrich (50-CCGGCGGACTTAAATCGGTTGTTAACTCGAGTTAA
CAACCGATTTAAGTCCGTTTTTG-30) and cloned in the pSuper vector
(OligoEngine) downstream the H1 promoter. H1-shRNATRIM33 fragment was
then cloned in the pTRIP/DU3-EF1a-GFP, where the GFP coding sequence is
under the control of the EF1a promoter. All the constructs were veriﬁed by
sequencing. Lentiviral vector production and cells transduction were carried out as
described42. GFP-positive cells were sorted and used in functional assays.
Luciferase assays. A 391 bp DNA fragment of murine Ifnb1 promoter was
obtained by PCR on genomic DNA and cloned into the pGL3 Basic vector
(Promega) using KpnI and XhoI sites. A 408 bp DNA fragment spanning the
 15 kb PU.1/TRIM33-binding site was obtained by PCR of genomic DNA and
cloned upstream of the 391 bp DNA fragment of murine Ifnb1 promoter into the
pGL3 Basic vector. After sequencing of the different constructs, RAW 264.7 cells
were transfected using JetPEI (PolyPlus-transfection) with the indicated constructs
and the TK-renilla reporter vector (Promega), as an internal control for normal-
ization. Twenty-four hours after transfection, cells were activated with LPS
(100 ngml 1) and luciferase activity was determined using the dual-luciferase
reporter assay (Promega). Fireﬂy luciferase activity was normalized with respect to
renilla luciferase activity.
Genomic deletions of ICE with the CRISPR/CAS9 system. Two guides RNA
(gRNA) were designed to delete a 1,361 bp fragment containing the  15 kb region
using the CRISPR Design Tool (http://tools.genome-engineering.org), to minimize
the number of off-target sites. Sequences for gRNA 5A2 and 3A are 50-TTC
TCGTTCATTGTTAGCGA-30 and 50-CTCTAGTTTAGACGTTTAAC-30,
respectively. Singles gRNA were then cloned into the LentiCRISPRv2 (Addgene)
vector, which contains the human CAS9-coding sequence, using BsmBI cloning
sites. Lentivirus were produced and co-transduced into RAW 264.7 and NIH3T3.
After puromycin selection (3mgml 1, Sigma Aldrich), cells were clonally isolated
by ﬂuorescence-activated cell sorting and individual clones were screened for
deletion by PCR using the following primers: F5-1:50-TGACGACAAATGTGGT
ACTGG-30; F3-1:50-CAGGCGAAAGGGAAACTAAA-30 ; and R3-1:50-TAGGAG
TGGCAGATGGGAAG-30 .
Deletions of 100 or 176 bp were carried out using one gRNA guide (50-AAA
CACGTTAGTTGTCAGAC-30) ﬂanking the PU.1/TRIM33 site at the ICE and
cloned into the LentiCRISPRv2 vector as above. After puromycin selection and
clonal isolation, WT and ICE / RAW 264.7 cells were identiﬁed by PCR using
the following primers: F: 50-AGCAAAGCCGAAGAAGACAC-30 and R: 50-GGA
AGAGGACGAGAGAACCA-30 .
All the clones were veriﬁed by sequencing of a 2 kb genomic region containing
the ICE.
Protein extraction and western blot. Total proteins from BMDM or iM were
extracted using lysis buffer (50mM Tris pH8, 300mM NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 1mM EDTA, phosphatase inhibitor cocktail-1 and -2
(Sigma Aldrich) and complete protease inhibitor cocktail (Roche)). Proteins were
separated on 3–8% Tris-Acetate gel or 4–12% Bis Tris gel (Life Technologies),
transferred on a nitrocellulose membrane (Amersham) and blotted with the
indicated antibodies. Following staining with HRP-coupled secondary antibodies,
the proteins were detected with ECL Prime by chemiluminescence (Amersham).
Antibodies. The following antibodies were used in western blot and ChIP:
TRIM33 (3E9, Euromedex for WB (1:1,000); A301-059A, Bethyl for ChIP (1:100)),
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c-JUN (sc-1694X, Santa Cruz (1:200)), p65 (sc-372X, Santa Cruz (1:200)), RNA Pol
II (sc-899X, Santa Cruz (1:200)), H3K4me3 (07-473, Millipore (1:500)), PU.1
(sc-352X, Santa Cruz (1:10,000 for western blot; 1:500 for ChIP)), p300 (sc-585X,
Santa Cruz), AcH3 (06-599, Millipore (1:500)), H3K4me1 (ab-8895, Abcam
(1:500)), Flag (M2 monoclonal, Sigma Aldrich (1:1,000)), CBP (A-22, sc-369,
Santa Cruz (1:1,000)), b-actin (A5441, Sigma Aldrich (1:10,000)).
Primer sequences. The following primer sequences were used in quantitative
RT-PCR, ChIP and 3C-seq: Ifnb1 F: 50-CTGGCTTCCATCATGAACAA-30 ; Ifnb1
R: 50-AGAGGGCTGTGGTGGAGAA-30 ; Ifna F: 50-GGATGTGACCTTCCTCAG
ACTC-30; Ifna R: 50-ACCTTCTCCTGCGGGAATCCAA-30 ; Hprt F: 50-GCTGGT
GAAAAGGACCTCT-30; Hprt R: 50-CACAGGACTAGAACACCTGC-30 ; Ifnb1
promoter F: 50-CCACCTGTTGTTCATGATGG-30; Ifnb1 promoter R: 50-CATT
CTCACTGCAGCCTTTG-30 ; Ifnb1 ICE F: 50-CCAAGGGTTGCGTAATGAAC-30 ;
Ifnb1 ICE R: 50-CCCGATCTTCAAATCCAGTC-30; Ifnb1 þ 2,5 kb F: 50-TAGCT
TCCATGCCCAGTTTC-30 ; Ifnb1 þ 2,5 kb R: 50-CCAAAAGTATGCCCATC
ACC-30; b-globin major promoter F: 50-GAAGCCTGATTCCGTAGAGC-30 ;
b-globin major promoter R: 50-CAACTGATCCTACCTCACCTTATATGC-30 ;
ICE EcoRI primer: 50-AATGATACGGCGACCACCGAACACTCTTTCCCTACA
CGACGCTCTTCCGATCT-30 followed by a 4nt tag and 50-GATGGCACACCTT
GAATTC-30 ; ICE DpnII primer: 50-CAAGCAGAAGACGGCATACGAGACGA
CAAATGTGGTACTG-30 ; Ifnb1 EcoRI primer: 50-AATGATACGGCGACCACC
GAACACTCTTTCCCTACACGACGCTCTTCCGATCT-30 followed by a 4nt
tag and 50-GGGTGTTCTATTTTATCAATAC-30 ; Ifnb1 DpnII primer: 50-CAA
GCAGAAGACGGCATACGATTTCTAGAGTTTCCGACTCTG-30 .
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